Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists

The metabolic syndrome

Robert H. Eckel, KGMM Alberti, Scott M. Grundy et al. · The Lancet · 2010 · 6.3K citations

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties

Peter Ertl, Bernhard Rohde, Paul M. Selzer · Journal of Medicinal Chemistry · 2000 · 3K citations

Pharmacy, Chemistry, Pharmacology +15

Insulin Resistance in Essential Hypertension

Eleuterio Ferrannini, G. Buzzigoli, Riccardo C. Bonadonna et al. · New England Journal of Medicine · 1987 · 2.4K citations

Medicine, Endocrinology, Physiology +6

Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity

Stephen C. Benson, Harrihar A. Pershadsingh, Christopher Ho et al. · Hypertension · 2004 · 1.1K citations

Medicine, Endocrinology, Pharmacology +17